**Clinical Study**

**Short-Term Effect of Pitavastatin Treatment on Glucose and Lipid Metabolism and Oxidative Stress in Fasting and Postprandial State Using a Test Meal in Japanese Men**

Hirokazu Kakuda, Junji Kobayashi, Mio Nakato, and Noboru Takekoshi

1 Kakuda Clinic, Takamatsu Nat15-1, Kahoku, Ishikawa 929-1215, Japan
2 Department of General Medicine, Kanazawa Medical University, I-1 Daigaku Uchinada, Kahoku, Ishikawa Prefecture 920-0293, Japan
3 Kanazawa Medical University, I-1 Daigaku Uchinada, Kahoku, Ishikawa Prefecture 920-0293, Japan

Correspondence should be addressed to Junji Kobayashi; mary@kanazawa-med.ac.jp

Received 3 September 2013; Revised 10 November 2013; Accepted 12 November 2013

Academic Editor: Jeffrey Cohn

Copyright © 2013 Hirokazu Kakuda et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**Introduction.** The objective of this study was to clarify how pitavastatin affects glucose and lipid metabolism, renal function, and oxidative stress.

**Methods.** Ten Japanese men (average age of 33.9 years) were orally administered 2 mg of pitavastatin for 4 weeks. Postprandial glucose, lipoprotein metabolism, and oxidative stress markers were evaluated at 0 and 4 weeks of pitavastatin treatment (2 mg once daily) with a test meal consisting of total calories: 460 kcal, carbohydrates: 56.5 g (226 kcal), protein: 18 g (72 kcal), lipids: 18 g (162 kcal), and NaCl: 1.6 g. Metabolic parameters were measured at 0, 60, and 120 minutes after test meal ingestion.

**Results.** After administration of pitavastatin, serum total cholesterol, low-density lipoprotein cholesterol, apolipoprotein B, arachidonic acid, insulin, and adjusted urinary excretion of uric acid decreased, whereas creatinine clearance ($C_{Cr}$) and uric acid clearance ($C_{UA}$) increased. And postprandial versus fasting urine 8-hydroxydeoxyguanosine remained unchanged, while postprandial versus fasting isoprostane decreased after pitavastatin treatment. Next, we compared postprandial glucose and lipid metabolism after test meal ingestion before and after pitavastatin administration. Incremental areas under the curve significantly decreased for triglycerides ($P < 0.05$) and remnant-like particle cholesterol ($P < 0.01$), while those for apolipoprotein E (apoE), glucose, insulin, and high-sensitivity C-reactive protein remained unchanged.

**Conclusion.** Pitavastatin improves postprandial oxidative stress along with hyperlipidemia.

1. **Introduction**

It has been generally recognized that postprandial hyperglycemia and hyperlipidemia are highly related to the development of atherosclerosis [1–5]. Hyperglycemia is known to damage vascular endothelial cells, increase oxidative stress, promote the expression of adhesion molecules, and inhibit Nitric Oxide (NO) production [6]. Remnant lipoprotein, an important component of postprandial hyperlipidemia, promotes foam cell formation of macrophages and proliferation of smooth muscle cells [7]. A very recent study on a large number of subjects demonstrated that remnant cholesterol was a causal risk factor for ischemic heart disease [8].

Lipid-lowering drugs, such as statins, fibrates, and ezetimibe are considered to be useful for the treatment of postprandial hyperlipidemia [9–15]. Pitavastatin, a member of the medication class of statins, has been available in the market in Japan since 2003. It has been well recognized that this statin is markedly effective in reducing low-density lipoprotein cholesterol (LDL-C), triglycerides (TG), and increasing high-density lipoprotein cholesterol (HDL-C), while it is scarcely metabolized by hepatic drug-metabolizing enzymes cytochrome P450 (CYP) [16–21]. As a consequence, pitavastatin is most likely to be appropriate for patients with metabolic syndrome with high LDL, low HDL, and diabetes mellitus. To the best of our knowledge, however, there are
few studies on the effect of pitavastatin on postprandial hyperlipidemia [22–24].

In addition, there is no previous study on the effect of pitavastatin on oxidative stress markers in postprandial states. 8-Hydroxydeoxyguanosine (8-OHdG) and isoprostane are important markers for oxidative stress [25, 26]. Isoprostanes are chemically stable, free radical-catalyzed products of arachidonic acid (AA) that are structural isomers of conventional prostaglandins [27].

With this background, in this study we investigated the effect of pitavastatin treatment on glucose and lipoprotein metabolism and oxidized stress markers in the postprandial state using a mixed meal consisting of fat, glucose and proteins, and an established test meal [28] for the evaluation of both postprandial hyperglycemia and hyperlipidemia.

2. Material and Methods

2.1. Study Subjects. Japanese men, who agreed to undergo pitavastatin treatment and mixed meal test, were involved in this study (n = 10; age 33.9 ± 10.1 years; body height 172.0 ± 4.3 cm; body weight 80.2 ± 25.3 kg; body mass index (BMI) 27.0 ± 8.3 kg/m²; waist circumference 88.5 ± 18.9 cm). None of them had received medication.

2.2. Sample Collection. The subjects were not allowed to eat anything after 8 pm the day before blood sampling. Smoking was not allowed on the day of the examination. They were not allowed to intake alcohol two days before the examination. On the morning of the day of examination, the study subjects did a complete urination and took 100 mL of water at 8 am, and then did a second urination right before blood sampling (at 0 min), followed by the oral ingestion of a test meal (JANEF E460F18, Q.P. Co., Tokyo, Japan) consisting of total calories 460 kcal, carbohydrates 56.5 g (226 kcal, 49.1%), Protein 18 g (72 kcal, 15.7%), lipids 18 g (162 kcal, 35.2%), and NaCl 1.6 g. The subjects spent 10 min of taking E460F18 with 120 mL of water and underwent blood and urine sampling at 60 minutes and 120 minutes. Pitavastatin administration (2 mg once daily) started from the next day for 4 weeks. After 4 weeks of pitavastatin administration, a meal tolerance test using E460F18 was again conducted exactly the same way it was done before starting pitavastatin.

2.3. Measurement of Metabolic Parameters. Cholesterol and triglycerides were measured by the enzyme method. HDL-C and LDL-C were measured by direct homogeneous assay methods using detergents. Quantification of remnant-like particles cholesterol (RLP-C) was conducted by a method using an immune-separation technique (Otsuka Pharmaceutical Co., Ltd.).

A total of 5 μL of plasma was mixed with 300 μL of lipoprotein separation medium consisting of a Sepharose gel suspension to which monoclonal antibodies directed against apoB-100 (JIH) and apoA-1 had been attached. The separation medium was gently mixed for 120 min, and thereafter allowed to settle for another 15 min. The cholesterol content (RLP-C) was assayed enzymatically in the supernatant with an autoanalyzer. Serum Insulin levels were measured using enzyme-linked immunosorbent assay kits (Cosmo Bio Co., Ltd., Tokyo, Japan). Urinary 8-Hydroxydeoxyguanosine (8-OHdG) and levels were measured using enzyme-linked immunosorbent assay kits (Cosmo Bio Co., Ltd., Tokyo, Japan). Urinary isoprostane levels were measured using enzyme-linked immunosorbent assay kits (Funakoshi Co., Ltd., Tokyo, Japan).

High-sensitivity C-reactive protein (hsCRP) levels were determined using an enzyme-linked immunosorbent assay kit (Dade Behring Marburg GmbH, Tokyo, Japan).

2.4. Analysis of Postprandial Lipid Metabolism. Postprandial metabolism was quantified by calculating the incremental area under the curve (iAUC) using each value at 0 minutes, 60 minutes, and 120 minutes after E460F18 loading. Results are presented as mean ± sd. Differences between parameters obtained before and after pitavastatin therapy were evaluated by paired Student’s t-test analysis.

Parameters that did not distribute normally (BMI, triglycerides, insulin, and HOMA-R) were analyzed by The Wilcoxon signed-rank test. Dunnett’s test was used for the multiple comparisons.

2.5. Ethics and Consent. This work was carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans.

Informed consent was obtained from all of the participants. The institutional review board in Kanazawa Medical University Hospital approved the experimental protocol, and all of the subjects provided informed consent to participate in the study.

3. Results

3.1. Changes in Metabolic Parameters in Fasting States before and after Pitavastatin Treatment. Table 1 shows changes in each indicator in fasting states before (at 0 weeks) and at 4 weeks after pitavastatin administration (2 mg/day). Four-week-pitavastatin treatment was not associated with changes in body mass index at all. There were reductions in total cholesterol (TC) LDL-C (direct method) and apolipoprotein B (apo B). There were no significant changes in fasting TG and RLP-C. Among 4 types of fatty acid, there was a significant reduction in arachidonic acid (AA). There was no significant change in plasma glucose but there was a reduction in fasting insulin.

No significant changes were observed in hsCRP and urine 8-OHdG. There were considerable increases in Ccr, CUA, and R (CUA/Ccr× 100%) and a decrease in adjusted urinary excretion of uric acid.

3.2. Changes in Time-Course of Lipid Parameters after Oral Loading of a Test Meal E460F18 before and after Pitavastatin Treatment. Figure 1 through Figure 3 show differences in the time course of metabolic parameters after E460F18 loading between before (at 0 weeks) and after (at 4 weeks) pitavastatin
### Table 1: Fasting metabolic parameters at 0 and 4 weeks after pitavastatin.

| Parameter                                      | 0 Weeks                        | 4 Weeks                        | P    |
|------------------------------------------------|-------------------------------|-------------------------------|------|
| Body mass index (kg/m²)                        | 23.4 (21.3–29.2)              | 23.7 (21.7–29.4)              | 0.557|
| Total cholesterol (mg/dL)                      | 197.9 ± 23.6                  | 156.5 ± 16.2                  | 0.0001|
| Low-density lipoprotein cholesterol (mg/dL)    | 121.5 ± 22.4                  | 81.9 ± 15.1                   | <0.0001|
| High-density lipoprotein cholesterol (mg/dL)   | 56.6 ± 10.1                   | 56.8 ± 9.4                    | 0.8321|
| Triglycerides (mg/dL)                          | 98.5 (78.0–138.8)             | 89.5 (63.0–132.8)             | 0.287|
| Remnant-like particle cholesterol (mg/dL)      | 4.57 ± 3.25                   | 2.91 ± 1.38                   | 0.1239|
| FFA (mEq/L)                                    | 0.52 ± 0.19                   | 0.51 ± 0.23                   | 0.8926|
| Apolipoprotein A1 (mg/dL)                      | 138.9 ± 13.7                  | 141.6 ± 12.6                  | 0.3207|
| Apolipoprotein B (mg/dL)                       | 89.6 ± 23.0                   | 66.6 ± 13.3                   | 0.0004|
| Apolipoprotein E (mg/dL)                       | 3.29 ± 1.17                   | 2.80 ± 0.63                   | 0.0735|
| Arachidonic acid (µg/mL)                       | 184.9 ± 32.2                  | 166.1 ± 31.5                  | 0.0485|
| Eicosapentaenoic acid (µg/mL)                  | 60.2 ± 39.2                   | 76.8 ± 55.5                   | 0.3319|
| Docosahexaenoic acid (µg/mL)                   | 121.0 ± 55.7                  | 113.9 ± 53.8                  | 0.6055|
| Glucose (mg/dL)                                | 92.0 ± 10.6                   | 89.9 ± 12.2                   | 0.4502|
| Insulin (µU/mL)                                | 5.9 (4.9–16.3)                | 5.9 (2.8–15.7)                | 0.028 |
| HOMA-R                                         | 1.28 (1.12–3.80)              | 1.26 (0.56–3.47)              | 0.322 |
| High sensitivity CRP (mg/L)                    | 0.0683 ± 0.0791               | 0.0436 ± 0.0566               | 0.187 |
| Urinary 8OHdG (ng/mgCr)                        | 7.99 ± 1.70                   | 7.25 ± 2.97                   | 0.1882|
| Urinary isoprostone (ng/mgCr)                  | 2.56 ± 0.68                   | 2.80 ± 1.03                   | 0.4423|
| Urinary isoprostone production rate (ng/kg/hour)| 2.32 ± 1.24                  | 2.65 ± 1.19                   | 0.4894|
| Serum creatinine (mg/dL)                       | 0.87 ± 0.09                   | 0.86 ± 0.12                   | 0.8143|
| eGFR (mL/min/1.73 m²)                          | 84.6 ± 12.1                   | 85.9 ± 14.8                   | 0.5168|
| Albumin/creatinine ratio (mg/gCr)              | 6.82 ± 7.49                   | 5.39 ± 5.79                   | 0.4383|
| Ccr (mL/minute)                                | 98.1 ± 34.4                   | 134.2 ± 31.0                  | 0.0431|
| Serum uric acid (mg/dL)                        | 5.97 ± 1.17                   | 5.82 ± 0.76                   | 0.4786|
| CUA (mL/minute)                                | 5.1 ± 2.4                     | 7.8 ± 1.9                     | 0.0072|
| CUA/Cr (%)                                     | 5.1 ± 1.7                     | 6.0 ± 1.7                     | 0.0409|
| Uric acid excretion (mg/gCr)                   | 353.4 ± 157.8                 | 405.3 ± 129.9                 | 0.2385|
| Adjusted urinary excretion of uric acid (mg/kg/hour)| 1.75 ± 0.73                   | 0.98 ± 0.76                   | 0.0378|

Values are shown as mean ± standard deviation. BMI, triglycerides, insulin, and HOMA-R are shown as median and interquartile range. HOMA-R: homeostasis model assessment ratio; 8OHdG: 8-Hydroxydeoxyguanosine; eGFR: estimated glomerular filtration rate; Ccr: creatinine clearance; CUA: uric acid clearance.

**Figure 1:** Changes in each parameters related to lipids after oral loading of E460F18 (a), triglycerides; (b), remnant-like protein cholesterol; (c), apolipoprotein E; Data are presented as mean ± standard deviation. ns, not significant.
Table 2: Changes in incremental area under the curve (iAUC) for each metabolic parameter after E460F18 loading at 0 and 4 weeks of pitavastatin.

| Parameter                        | 0 week     | 4 week     | P  |
|----------------------------------|------------|------------|----|
| Triglycerides (mg/dL)            | 3885 (2565–6480) | 2745 (1883–4508) | 0.007 |
| Remnant-like particle cholesterol | 166 ± 125 | 68 ± 85 | 0.0012 |
| Apolipoprotein E (mg/dL)         | 21 ± 29 | 4 ± 13 | 0.1333 |
| Glucose (mg/dL)                  | 882 ± 2175 | 1491 ± 2216 | 0.2289 |
| Insulin                          | 2342 (1202–3083) | 2664 (1441–5439) | 0.093 |
| Cr (mL/minute)                   | 5048 ± 7975 | 6058 ± 4660 | 0.7752 |
| Albumin creatinine ratio         | −68 ± 194 | −194 ± 312 | 0.2424 |
| UA (mL/minute)                   | 536 ± 317 | 534 ± 292 | 0.9920 |
| Adjusted urinary excretion of uric acid (mg/kg/hour) | −88 ± 55 | −37 ± 53 | 0.0442 |

Values are shown as mean ± standard deviation. Cr: creatinine clearance; UA: uric acid clearance. iAUC for triglycerides and insulin are shown as median and interquartile range.

Figure 2: Changes in each parameters related to glucose after oral loading of E460F18 (a), Glucose; (b), immunoreactive insulin; Data are presented as mean ± standard deviation. ns, not significant.

3.3. Changes in Time-Course of Parameters for Oxidative Stress Index after Oral Loading of a Test Meal E460F18 before and after Pitavastatin Treatment. We also analyzed changes in oxidative stress index after pitavastatin treatment. There was no difference in postprandial changes in urine 8-OHdG between before and after pitavastatin treatment, whereas the postprandial increase in urine isoprostanes observed before pitavastatin treatment tended to decrease after pitavastatin treatment (Figure 3).

4. Discussion
In this study we clarified that pitavastatin treatment produced considerable improvement in markers related to oxidative stress.
Cholesterol

stress as well as those related to lipid metabolism including RLP-C in postprandial states in Japanese men with abdominal obesity. This is the first study investigating pitavastatin effects on oxidative stress markers in postprandial states after test meal loading as well as fasting states.

For fasting states, pitavastatin treatment was associated with significant decreases in fasting insulin levels as well as decreases in fasting TC, LDL-C, and apoB.

For postprandial states, pitavastatin treatment was associated with marked reductions in TG-iAUC and more so in RLP-iAUC. Several studies show that plasma RLP-C, not TG, is an independent risk for the development of atherosclerotic disease [29, 30].

There are several studies on the effect of atorvastatin, another strong statin, on postprandial hyperlipidemia and the mechanisms of its improvement have been considered to be an inhibition of the production of very low-density lipoprotein (VLDL) caused by sustained inhibition of cholesterol synthesis in the liver [31] and increased lipoprotein lipase (LPL) activity leading to hydrolysis of TG-rich lipoproteins [11]. Parhofer et al. have suggested that atorvastatin promoted the uptake of chylomicron remnants by the liver through LDL receptors, leading to the improvement of postprandial lipid metabolism in normolipidemic subjects [13] and hypertriglyceridemic subjects [14]. It is also shown that atorvastatin inhibits the production of apolipoprotein CIII, leading to increases in LPL activity [12]. Compared with atorvastatin, there appears to be much less information available so far on the effect of pitavastatin on postprandial hyperlipidemia and the mechanism by which it exerts its effectiveness. Saiki et al. [32] have reported using preadipocyte 3T3L1 that among pravastatin, simvastatin, atorvastatin, and pitavastatin, pitavastatin was the strongest to increase the activity of LPL. Morikawa et al. have found that when using Hep G2 cells the effect of pitavastatin on the induction of LDL receptor was stronger compared with other statins [33]. Based on these findings, we suggest that in the current study pitavastatin increased the number of LDL receptors in the liver along with an increase in LPL activity, which in turn could cause the improvement of postprandial lipid metabolism. Moreover, other mechanisms could contribute to the improvement of postprandial lipid metabolism by pitavastatin. It has been suggested that pitavastatin decreases the expression of mRNA of microsomal triglyceride transfer protein (MTTP) from the liver in an animal model of postprandial hyperlipidemia [24, 34].

A postprandial increase in oxidative stress is considered to be an important contributor to the impairment of endothelial function, leading to the development of atherosclerosis and there is a study showing the close link between increases in both TG and that in oxidative stress [35]. Indeed in the current study, we found that increases in urine isoprostanes, an oxidative stress marker, in the postprandial states observed before pitavastatin treatment decreased after pitavastatin
treatment. To our knowledge, this is the first study suggesting that pitavastatin treatment inhibits the production of isoprostanes during postprandial states.

The mechanism by which this occurred has not been clarified yet, but there is a study suggesting the contribution of adiponectin to the reduction of isoprostanes during atorvastatin treatment [36]. Also, pitavastatin treatment is reported to be associated with increased adiponectin in hyperlipidemic patients with type II diabetes [37].

We also analyzed the effect of pitavastatin treatment on changes in renal function. Among them the present findings that Ccr increased after the treatment is compatible with our previous report [38]. We presume that this effect of pitavastatin could be related to the induction of endothelial NO synthase (eNOS) by this drug [39], since NO synthesis inhibition has been associated with decreases in renal plasma flow (RPF) and glomerular filtration rate (GFR) [40]. These observations suggest that pitavastatin may be a suitable drug for treatment of hyperlipidemia with chronic kidney disease (CKD).

The limitations of this study are that the sample size is small and study was done in a single arm. However, we conducted measurements of a wide range of metabolic markers at several time points in postprandial states as well as fasting states before and after pitavastatin treatment. Also it should be noted that to the best of our knowledge there have only been 2 clinical studies on the effect of pitavastatin on postprandial metabolism [22, 23], both of which mainly focused on the prevention of postprandial endothelial dysfunction after pitavastatin treatment.

In conclusion, the present findings suggest that in men with abdominal obesity, pitavastatin improves oxidative stress and renal function along with hyperlipidemia, especially in regards to remnant metabolism, in the postprandial state, contributing to the prevention of the development of atherosclerosis. It is also suggested that pitavastatin improves renal function.

Conflict of Interests

There is no conflict of interests for all of the authors regarding this work.

References

[1] Q. Qiao, S. Larsen, K. Borch-Johnsen et al., “Glucose tolerance and cardiovascular mortality. Comparison of fasting and 2-hour diagnostic criteria,” Archives of Internal Medicine, vol. 161, no. 3, pp. 397–405, 2001.
[2] M. Tominaga, H. Eguchi, H. Manaka, K. Igarashi, T. Kato, and A. Sekikawa, “Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose: the Funagata Diabetes Study,” Diabetes Care, vol. 22, no. 6, pp. 920–924, 1999.
[3] D. B. Zilversmit, "Atherogenesis: a postprandial phenomenon," Circulation, vol. 60, no. 3, pp. 473–485, 1979.
[4] F. Karpe, "Postprandial lipoprotein metabolism and atherosclerosis," Journal of Internal Medicine, vol. 246, no. 4, pp. 341–355, 1999.
[5] R. J. Havel, “Remnant lipoproteins as therapeutic targets,” Current Opinion in Lipidology, vol. 11, no. 6, pp. 615–620, 2000.
[6] D. Aronson and E. J. Rayfield, "How hyperglycemia promotes atherosclerosis: molecular mechanisms," Cardiovascular Diabetology, vol. 1, article 1, 2002.
[7] T. B. Twickler, G. M. Dallnga-Thie, J. S. Cohn, and M. J. Chapman, “Elevated remnant-like particle cholesterol concentration: a characteristic feature of the atherogenic lipoprotein phenotype,” Circulation, vol. 109, no. 16, pp. 1918–1925, 2004.
[8] A. Varbo, M. Benn, A. Tybaier-Hansen, A. B. Jorgensen, R. Frikke-Schmidt, and B. G. Nordestgaard, “Remnant cholesterol as a causal risk factor for ischemic heart disease,” Journal of the American College of Cardiology, vol. 61, pp. 427–436, 2012.
[9] T. C. Ooi, M. Cousins, D. S. Ooi, K. Nakajima, and A. L. Edwards, “Effect of fibers on postprandial remnant-like particles in patients with combined hyperlipidemia,” Atherosclerosis, vol. 172, no. 2, pp. 375–382, 2004.
[10] E. J. Schaefer, J. R. McNamara, T. Taylor et al., "Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects," The American Journal of Cardiology, vol. 93, no. 1, pp. 31–39, 2004.
[11] J. G. Schneider, M. Von Eynatten, K. G. Parhofer et al., “Atorvastatin improves diabetic dyslipidemia and increases lipoprotein lipase activity in vivo,” Atherosclerosis, vol. 175, no. 2, pp. 325–331, 2004.
[12] K. Schoonjans, J. Peinado-Onsurbe, J.-C. Fruchart, A. Tailleux, C. Fiévet, and J. Auwerx, “3-Hydroxy-3-methylglutaryl CoA reductase inhibitors reduce serum triglyceride levels through modulation of apolipoprotein C-III and lipoprotein lipase,” FEBS Letters, vol. 452, no. 3, pp. 160–164, 1999.
[13] K. G. Parhofer, P. H. R. Barrett, and P. Schwandt, “Atorvastatin improves postprandial lipoprotein metabolism in normolipidemic subjects,” The Journal of Clinical Endocrinology and Metabolism, vol. 85, no. 11, pp. 4224–4230, 2000.
[14] K. G. Parhofer, E. Laubach, and P. H. R. Barrett, “Effect of atorvastatin on postprandial lipoprotein metabolism in hypertriglyceridemic patients,” Journal of Lipid Research, vol. 44, no. 6, pp. 1192–1198, 2003.
[15] K. Yunoki, K. Nakamura, T. Miyoshi et al., “Ezetimibe improves postprandial hyperlipemia and its induced endothelial dysfunction,” Atherosclerosis, vol. 217, no. 2, pp. 486–491, 2011.
[16] T. Hayashi, K. Yokote, Y. Saito, and A. Iguchi, “Pitavastatin: efficacy and safety in intensive lipid lowering,” Expert Opinion on Pharmacotherapy, vol. 8, no. 14, pp. 2315–2327, 2007.
[17] T. Hiro, T. Kimura, T. Morimoto et al., “Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin [JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome study]],” Journal of the American College of Cardiology, vol. 54, no. 4, pp. 293–302, 2009.
[18] M.-A. Kawashiri, A. Nohara, H. Tada et al., “Comparison of effects of pitavastatin and atorvastatin on plasma coenzyme Q10 in heterozygous familial hypercholesterolemia: results from a crossover study,” Clinical Pharmacology and Therapeutics, vol. 83, no. 5, pp. 731–739, 2008.
[19] N. Poolsup, N. Sukomboon, K. Wongyaowarat, B. Rungkanphanon, P. Niyomrat, and S. Kongsuwan, “Meta-analysis
of the comparative efficacy and safety of pitavastatin and atorvastatin in patients with dyslipidemia,” Journal of Clinical Pharmacy and Therapeutics, vol. 37, no. 2, pp. 166–172, 2012.

[20] A. Corsini and R. Ceska, “Drugdrug interactions with statins: will pitavastatin overcome the statins Achilles heel?” Current Medical Research and Opinion, vol. 27, no. 8, pp. 1551–1562, 2011.

[21] A. L. Catapano, “Statin-induced myotoxicity: pharmacokinetic differences among statins and the risk of rhabdomyolysis, with particular Reference to pitavastatin,” Current Vascular Pharmacology, vol. 10, no. 2, pp. 257–267, 2012.

[22] H. Nagashima and M. Endo, “Pitavastatin prevents postprandial endothelial dysfunction via reduction of the serum triglyceride level in obese male subjects,” Heart and Vessels, vol. 26, no. 4, pp. 428–434, 2011.

[23] K. Arao, T. Yasu, T. Uemoto et al., “Effects of pitavastatin on fasting and postprandial endothelial function and blood rheology in patients with stable coronary artery disease,” Circulation Journal, vol. 73, no. 8, pp. 1523–1530, 2009.

[24] T. Aoki, Y. Yoshinaka, H. Yamazaki et al., “Triglyceride-lowering effect of pitavastatin in a rat model of postprandial lipemia,” European Journal of Pharmacology, vol. 444, no. 1-2, pp. 107–113, 2002.

[25] A. M. Nuernberg, P. D. Boyce, J. M. Cavallari, S. C. Fang, E. A. Eisen, and D. C. Christiani, “Urinary 8-isoprostane and 8-OHdG concentrations in boilermakers with welding exposure,” Journal of Occupational and Environmental Medicine, vol. 50, no. 2, pp. 182–189, 2008.

[26] A. A. Commodore, J. J. Zhang, Y. Chang et al., “Concentrations of urinary 8-hydroxy-2′-deoxyguanosine and 8-isoprostane in women exposed to woodsmoke in a cookstove intervention study in San Marcos, Peru,” Environment International, vol. 60, pp. 112–122, 2013.

[27] J. D. Morrow, K. E. Hill, R. E. Burk, T. M. Nammour, K. E. Badr, and L. J. Roberts II, “A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism,” Proceedings of the National Academy of Sciences of the United States of America, vol. 87, no. 23, pp. 9383–9387, 1990.

[28] E. Nagai, T. Katsuno, J.-I. Miyagawa et al., “Effects of miglitol in combination with intensive insulin therapy on blood glucose control with special Reference to incretin responses in type 1 diabetes mellitus,” Endocrine Journal, vol. 58, no. 10, pp. 869–877, 2011.

[29] J. R. McNamara, P. K. Shah, K. Nakajima et al., “Remnant-like particle (RLP) cholesterol is an independent cardiovascular disease risk factor in women: results from the Framingham Heart Study,” Atherosclerosis, vol. 154, no. 1, pp. 229–236, 2001.

[30] F. Karpe, S. Boquist, R. Tang, G. M. Bond, U. De Faire, and A. Hamsten, “Remnant lipoproteins are related to intima-media thickness of the carotid artery independently of LDL cholesterol and plasma triglycerides,” Journal of Lipid Research, vol. 42, no. 1, pp. 17–21, 2001.

[31] M. Guerin, P. Egger, W. L. Goff, C. Soudant, R. Dupuis, and M. John Chapman, “Atorvastatin reduces postprandial accumulation and cholesteryl ester transfer protein-mediated remodeling of triglyceride-rich lipoprotein subspecies in type IIB hyperlipidemia,” The Journal of Clinical Endocrinology and Metabolism, vol. 87, no. 11, pp. 4991–5000, 2002.

[32] A. Saiki, T. Murano, F. Watanabe, T. Oyama, Y. Miyashita, and K. Shirai, “Pitavastatin enhanced lipoprotein lipase expression in 3T3-L1 preadipocytes,” Journal of Atherosclerosis and Thrombosis, vol. 12, no. 3, pp. 163–168, 2005.

[33] S. Morikawa, M. Umetani, S. Nakagawa et al., “Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells,” Journal of Atherosclerosis and Thrombosis, vol. 7, no. 3, pp. 138–144, 2000.

[34] S. Lally, C. Y. Tan, D. Owens, and G. H. Tomkin, “Messenger RNA levels of genes involved in dysregulation of postprandial lipoproteins in type 2 diabetes: the role of Niemann-Pick C1-like 1, ATP-binding cassette, transporters G5 and G8, and of microsomal triglyceride transfer protein,” Diabetologia, vol. 49, no. 5, pp. 1008–1016, 2006.

[35] J.-H. Bae, E. Bassenge, K.-B. Kim et al., “Postprandial hypertriglyceridemia impairs endothelial function by enhanced oxidant stress,” Atherosclerosis, vol. 155, no. 2, pp. 517–523, 2001.

[36] R. Carnevale, P. Pignatelli, S. Di Santo et al., “Atorvastatin inhibits oxidative stress via adiponectin-mediated NADPH oxidase down-regulation in hypercholesterolemic patients,” Atherosclerosis, vol. 213, no. 1, pp. 225–234, 2010.

[37] S. Nomura, N. Inami, A. Shouzu et al., “The effects of pitavastatin, eicosapentaenoic acid and combined therapy on platelet-derived microparticles and adiponectin in hyperlipidemic, diabetic patients,” Platelets, vol. 20, no. 1, pp. 16–22, 2009.

[38] H. Kakuda, K. Kanasaki, D. Koya, and N. Takekoshi, “The administration of pitavastatin augments creatinine clearance associated with reduction in oxidative stress parameters: acute and early effects,” Clinical and Experimental Nephrology, vol. 17, pp. 240–247, 2013.

[39] B. Sadowitz, K. G. Maier, and V. Gahtan, “Basic science review: statin therapy-part I: the pleiotropic effects of statins in cardiovascular disease,” Vascular and Endovascular Surgery, vol. 44, no. 4, pp. 241–251, 2010.

[40] J. N. Bech, C. B. Nielsen, and E. B. Pedersen, “Effects of systemic NO synthesis inhibition on RPF, GFR, UNa, and vasoactive hormones in healthy humans,” American Journal of Physiology, vol. 270, no. 5, pp. F845–F851, 1996.